The functional genomics screening laboratory (FGSL), a joint venture between the Milner Institute, the Medical Research Council (MRC) and AstraZeneca, has opened a call for project proposals.
Call open to UK-based academics, small/medium-sized enterprises (SMEs) and pharma who have complex human in vitro models, such as organoids, co-culture models, etc., amenable to arrayed CRISPR screening.
Through setting up collaborations with successful applicants, the FGSL aims to support academic researchers, SMEs and pharma to gain access to arrayed functional genomics screening to better understand the biology represented by the model and where applicable, for target identification.
Although the new laboratory will not be fully operational until January 2025, the call for projects is opening now to allow sufficient time for reviewing and selecting the most suitable proposals, and establishing collaboration agreements to maximize use of the new laboratory as soon as it opens.
All information regarding the application process, the application form and arrayed CRISPR screens is available on the Functional Genomics Screening Laboratory space: Health Tech (C:HT) online community.
This is an open call for applications and the first review deadline is 20th May 2024. A second review of submitted applications is planned for November 2024
